The launch of the 750mcg teriparatide solution in Australia has seen limited distribution to date. Primarily designated for patients with severe skeletal fragility who have not responded to other treatments , access is strictly managed. Existing supply amounts are constrained , and individuals should confirm regarding their physician the current in